Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/2952 |
Resumo: | PURPOSE: To describe the clinical manifestations of presumed gadolinium toxicity in patients with normal renal function. MATERIALS AND METHODS: Participants were recruited from two online gadolinium toxicity support groups. The survey was anonymous and individuals were instructed to respond to the survey only if they had evidence of normal renal function, evidence of gadolinium in their system beyond 30days of this MRI, and no pre-existent clinical symptoms and/or signs of this type. RESULTS: 42 subjects responded to the survey (age: 28-69, mean 49.1±22.4years). The most common findings were: central pain (n=15), peripheral pain (n=26), headache (n=28), and bone pain (n=26). Only subjects with distal leg and arm distribution described skin thickening (n=22). Clouded mentation and headache were the symptoms described as persistent beyond 3months in 29 subjects. Residual disease was present in all patients. Twenty-eight patients described symptoms following administration of one brand of Gadolinium-Based Contrast Agent (GBCA), 21 after a single GBCA administration and 7 after multiple GBCA administrations, including: gadopentetate dimeglumine, n=9; gadodiamide, n=4; gadoversetamide, n=4; gadobenate dimeglumine, n=4; gadobutrol, n=1; gadoteridol, n=2; and unknown, n=4. CONCLUSIONS: Gadolinium toxicity appears to arise following GBCA administration, which appears to contain clinical features seen in Nephrogenic Systemic Fibrosis, but also features not observed in that condition. |
id |
RCAP_e3678d58aef720d0329d14e2354e6269 |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/2952 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a WhileAdultAgedContrast MediaFemaleGadoliniumGadolinium DTPAHeterocyclic CompoundsHumansMaleMeglumineMiddle AgedOrganometallic CompoundsPainProspective StudiesMagnetic Resonance ImagingCHLC IMAPURPOSE: To describe the clinical manifestations of presumed gadolinium toxicity in patients with normal renal function. MATERIALS AND METHODS: Participants were recruited from two online gadolinium toxicity support groups. The survey was anonymous and individuals were instructed to respond to the survey only if they had evidence of normal renal function, evidence of gadolinium in their system beyond 30days of this MRI, and no pre-existent clinical symptoms and/or signs of this type. RESULTS: 42 subjects responded to the survey (age: 28-69, mean 49.1±22.4years). The most common findings were: central pain (n=15), peripheral pain (n=26), headache (n=28), and bone pain (n=26). Only subjects with distal leg and arm distribution described skin thickening (n=22). Clouded mentation and headache were the symptoms described as persistent beyond 3months in 29 subjects. Residual disease was present in all patients. Twenty-eight patients described symptoms following administration of one brand of Gadolinium-Based Contrast Agent (GBCA), 21 after a single GBCA administration and 7 after multiple GBCA administrations, including: gadopentetate dimeglumine, n=9; gadodiamide, n=4; gadoversetamide, n=4; gadobenate dimeglumine, n=4; gadobutrol, n=1; gadoteridol, n=2; and unknown, n=4. CONCLUSIONS: Gadolinium toxicity appears to arise following GBCA administration, which appears to contain clinical features seen in Nephrogenic Systemic Fibrosis, but also features not observed in that condition.ElsevierRepositório do Centro Hospitalar Universitário de Lisboa Central, EPESemelka, RCRamalho, JVakharia, AAlObaidy, MBurke, LMJay, MRamalho, M2018-03-15T15:28:26Z20162016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2952engMagn Reson Imaging. 2016 Dec;34(10):1383-139010.1016/j.mri.2016.07.016info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:40:29Zoai:repositorio.chlc.min-saude.pt:10400.17/2952Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:16.328042Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
title |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
spellingShingle |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While Semelka, RC Adult Aged Contrast Media Female Gadolinium Gadolinium DTPA Heterocyclic Compounds Humans Male Meglumine Middle Aged Organometallic Compounds Pain Prospective Studies Magnetic Resonance Imaging CHLC IMA |
title_short |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
title_full |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
title_fullStr |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
title_full_unstemmed |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
title_sort |
Gadolinium Deposition Disease: Initial Description of a Disease that Has Been Around for a While |
author |
Semelka, RC |
author_facet |
Semelka, RC Ramalho, J Vakharia, A AlObaidy, M Burke, LM Jay, M Ramalho, M |
author_role |
author |
author2 |
Ramalho, J Vakharia, A AlObaidy, M Burke, LM Jay, M Ramalho, M |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Semelka, RC Ramalho, J Vakharia, A AlObaidy, M Burke, LM Jay, M Ramalho, M |
dc.subject.por.fl_str_mv |
Adult Aged Contrast Media Female Gadolinium Gadolinium DTPA Heterocyclic Compounds Humans Male Meglumine Middle Aged Organometallic Compounds Pain Prospective Studies Magnetic Resonance Imaging CHLC IMA |
topic |
Adult Aged Contrast Media Female Gadolinium Gadolinium DTPA Heterocyclic Compounds Humans Male Meglumine Middle Aged Organometallic Compounds Pain Prospective Studies Magnetic Resonance Imaging CHLC IMA |
description |
PURPOSE: To describe the clinical manifestations of presumed gadolinium toxicity in patients with normal renal function. MATERIALS AND METHODS: Participants were recruited from two online gadolinium toxicity support groups. The survey was anonymous and individuals were instructed to respond to the survey only if they had evidence of normal renal function, evidence of gadolinium in their system beyond 30days of this MRI, and no pre-existent clinical symptoms and/or signs of this type. RESULTS: 42 subjects responded to the survey (age: 28-69, mean 49.1±22.4years). The most common findings were: central pain (n=15), peripheral pain (n=26), headache (n=28), and bone pain (n=26). Only subjects with distal leg and arm distribution described skin thickening (n=22). Clouded mentation and headache were the symptoms described as persistent beyond 3months in 29 subjects. Residual disease was present in all patients. Twenty-eight patients described symptoms following administration of one brand of Gadolinium-Based Contrast Agent (GBCA), 21 after a single GBCA administration and 7 after multiple GBCA administrations, including: gadopentetate dimeglumine, n=9; gadodiamide, n=4; gadoversetamide, n=4; gadobenate dimeglumine, n=4; gadobutrol, n=1; gadoteridol, n=2; and unknown, n=4. CONCLUSIONS: Gadolinium toxicity appears to arise following GBCA administration, which appears to contain clinical features seen in Nephrogenic Systemic Fibrosis, but also features not observed in that condition. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 2016-01-01T00:00:00Z 2018-03-15T15:28:26Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/2952 |
url |
http://hdl.handle.net/10400.17/2952 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Magn Reson Imaging. 2016 Dec;34(10):1383-1390 10.1016/j.mri.2016.07.016 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131298791424000 |